- NeuroKey-3™ measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer’s Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and more.
- NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.
- NeuroKey-3™ is now commercially available through Inoviv for drug developers to gather valuable data for their clinical trials.
LONDON, March 1, 2024 /PRNewswire/ — Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma. The launch of NeuroKey-3™ signifies an important milestone in Inoviv’s mission to generate novel molecular insights that transform drug development and healthcare globally. Inoviv will unveil NeuroKey-3™ at AD/PD 2024 on March 5, 2024.
NeuroKey-3™ is the world’s first commercially available disease-targeted assay providing absolute quantification from plasma of a unique set of proteins linked to Alzheimer’s Disease and Dementia. The comprehensive assay and end-to-end service delivers highly robust and reproducible data to quantify low-level analytes and provides clinical researchers with a full biomarker report containing statistical analysis, graphical data representations, correlation matrices, and quantitative values.
Read full article on prnewswire.com
